What question did this study set out to answer?

This review investigates the relationship between atrial fibrillation and myeloproliferative neoplasms, focusing on the NLRP3 inflammasome as a common mediator.

January 10, 2026Thrombosis and Haemostasis

Atrial Fibrillation in Philadelphia Chromosome–negative Myeloproliferative Neoplasms: Thromboinflammatory Crosstalk with a Focus on the NLRP3 Inflammasome

View Full Paper

Ask AI

Bookmark

Key result

NLRP3 inflammasome inhibition emerges as a promising adjunct for thrombosis and inflammation in MPN and AF.

Why the study?

Patients with coexisting MPNs and AF share a proinflammatory phenotype but remain undertreated and poorly characterized, with no specific antithrombotic guidelines.

Design

Review

Authors

ODOlga DemskaNicolaus Copernicus University MSMarta Szandruk-BenderWroclaw Medical University NBNiels Eske BruunGeneral Cardiology

Discussion

Member takes

Implication

NLRP3 inhibition merits prospective trials in MPN-AF overlap; leaves open whether it improves antithrombotic outcomes.

Key Points

This review investigates the relationship between atrial fibrillation and myeloproliferative neoplasms, focusing on the NLRP3 inflammasome as a common mediator.
Exploration of the pathophysiologic convergence of MPNs and AF.
Critical evaluation of the role of NLRP3 inflammasome and its downstream cytokines.
Analysis of the effects of neutrophil extracellular traps on thrombosis and atrial remodeling.
Identified NLRP3 inflammasome as central in linking MPNs and AF pathology.
Proposed NLRP3 inhibition as a promising treatment strategy in coexisting conditions.
Highlighted the need for prospective studies to improve antithrombotic management in this population.

Structured PICO

Population

Patients with coexisting Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) and atrial fibrillation (AF)

The NLRP3 inflammasome represents a key pathophysiologic link between myeloproliferative neoplasms and atrial fibrillation, offering a potential target for adjunctive therapy.

Cite This Study

Demska et al. (2025) studied this question. NLRP3 inflammasome inhibition is proposed as a promising adjunctive strategy for managing thrombosis and inflammation in patients with both myeloproliferative neoplasms and atrial fibrillation.

synapsesocial.com/papers/6963222f91e05aa366cb8c00 https://doi.org/10.1055/a-2767-0451

Topics

Atrial fibrillation Persistent AF management

View Full Paper

Ask AI

Bookmark

Atrial Fibrillation in Philadelphia Chromosome–negative Myeloproliferative Neoplasms: Thromboinflammatory Crosstalk with a Focus on the NLRP3 Inflammasome

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Atrial Fibrillation in Philadelphia Chromosome–negative Myeloproliferative Neoplasms: Thromboinflammatory Crosstalk with a Focus on the NLRP3 Inflammasome

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider